{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T18:49:07.863163",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 143,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "long-term survival",
        "perioperative mortality",
        "treatment-related mortality",
        "death",
        "survival",
        "improved survival",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "time to deterioration",
        "time to progression of the tumor",
        "progression-free state",
        "progressive illness state",
        "death state"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "tumor response rate",
        "tumour response (mRECIST)",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "partial response (PR)",
        "complete response (CR)",
        "complete remission",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "clinical benefit rate (CBR)",
        "tumor reduction",
        "local control",
        "local tumour control",
        "success rate (downstaging/bridging)",
        "disease control",
        "disease recurrence",
        "recurrence",
        "early detection of recurrence",
        "progression",
        "disease progression",
        "tumour spread (TNM system)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "down-staging",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time-to-progression",
        "time to progression of the tumor",
        "progression",
        "progression-free survival (PFS)",
        "progression-free survivorship"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (CTCAE v5.0)",
        "adverse reactions (general)",
        "adverse reactions (grade-III/IV)",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "treatment-emergent adverse events (TEAEs)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "complications",
        "complications (general)",
        "post-treatment complications",
        "long-term treatment-related complications",
        "undesirable effects",
        "side-effects (general)",
        "intraoperative complications",
        "morbidity",
        "mortality",
        "dropout rate for toxicity",
        "treatment-related deaths",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "discontinuation of treatment due to adverse events",
        "hand-foot skin reaction",
        "hand-foot-skin reaction",
        "hand-foot syndrome",
        "hand feeding reactions",
        "skin rash",
        "rash",
        "desquamation",
        "skin desquamation",
        "dry skin",
        "erythema",
        "pruritus",
        "dermatitis exfoliative",
        "acne",
        "hyperkeratosis",
        "alopecia",
        "folliculitis",
        "diarrhoea",
        "nausea",
        "vomiting",
        "constipation",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "back pain",
        "limb pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "fatigue",
        "fatigue (EORTC QLQ-HCC18)",
        "asthenia",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "influenza like illness",
        "decreased appetite",
        "anorexia",
        "weight loss",
        "decreased weight",
        "dysphonia",
        "dysgeusia",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "gastro oesophageal reflux disease",
        "nutrition",
        "body image",
        "jaundice (EORTC QLQ-HCC18)",
        "liver failure",
        "hepatic encephalopathy",
        "hepatic insufficiency",
        "liver disorders",
        "liver-related morbidity",
        "portal vein thrombosis",
        "tumour haemorrhage",
        "bleeding",
        "haemorrhagic events",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "ischaemic stroke",
        "cerebral vascular accident",
        "arterial thromboembolic events",
        "arterial hypertension",
        "hypertension",
        "proteinuria",
        "renal events",
        "renal failure",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypophosphataemia",
        "hypoglycaemia",
        "hyperthyroidism",
        "hypothyroidism",
        "diabetes mellitus",
        "infections",
        "sepsis",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "secondary cancer",
        "squamous cell cancer of the skin",
        "keratoacanthoma",
        "transient increase in transaminases",
        "increased ALT activity",
        "increased amylase",
        "increased lipase",
        "creatinine increase",
        "ALT increase",
        "AST increase",
        "QTc prolongation",
        "pleural effusion",
        "dyspnoea",
        "cough",
        "shortness of breath",
        "respiratory failure",
        "sudden death",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "cardiovascular arrest",
        "flushing",
        "rhinorrhoea",
        "tinnitus",
        "peripheral sensory neuropathy",
        "depression",
        "psychological complaints",
        "psychosocial complaints",
        "general complaints",
        "distress",
        "physical complaints",
        "hypody",
        "erectile dysfunction",
        "infusion reactions",
        "hypersensitivity to monitoring",
        "rebleeding",
        "postoperative softening",
        "gallbladder abscess",
        "lymphoedema",
        "nutrition",
        "early diagnosis",
        "false positives"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "discontinuation of treatment due to adverse events",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "EQ-5D visual analogue scale",
        "European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep",
        "SF-36",
        "visual analogue scale",
        "FHSI-8 questionnaire",
        "overall quality of life (measured with a validated and reliable instrument)",
        "health-related quality of life (HRQoL)",
        "health-related quality of life",
        "health status (EQ-5D visual analogue scale)",
        "health status",
        "global health status (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)"
      ],
      "functional_status": [
        "overall condition (ECOG Performance Status)",
        "Barcelona Clinic Liver Cancer (BCLC) staging system",
        "prognosis (BCLC staging system)",
        "prognosis (Child-Pugh score)",
        "prognosis (MELD score)",
        "liver function",
        "liver function (Child-Pugh scale)"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue (EORTC QLQ-HCC18)",
        "symptoms",
        "distress",
        "physical complaints",
        "psychological complaints",
        "psychosocial complaints",
        "general complaints"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness analysis",
        "cost-benefit analysis",
        "cost per quality-adjusted life year (QALY)",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights",
        "health state utility values"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "need for use of medical resources",
        "resource utilization"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "false positives",
        "early diagnosis",
        "risk of developing hepatocellular carcinoma",
        "risk indicator for hepatocellular carcinoma development",
        "down-staging",
        "donor morbidity",
        "success rate (downstaging/bridging)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "undesirable effects",
        "histological and prognostic parameters",
        "immunohistochemical confirmation",
        "genetic diagnosis"
      ],
      "biomarkers": [
        "alpha-fetoprotein (AFP) monitoring",
        "plasma pharmacokinetics parameters",
        "pharmacokinetic parameters",
        "pharmacokinetic/pharmacodynamic relationship",
        "vital signs",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography"
      ]
    }
  }
}